Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06848348 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A Phase 2 study of Chemotherapy Induced Neuropathic Pain, sponsored by Dogwood Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06848348: Recruiting Phase 2 study of Chemotherapy Induced Neuropathic Pain, sponsored by Dogwood Therapeutics.
NCT06848348 is a Phase 2 study of Chemotherapy Induced Neuropathic Pain that is actively recruiting participants, run by Dogwood Therapeutics. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06848348, a Phase 2 study of Chemotherapy Induced Neuropathic Pain, is actively recruiting participants, sponsored by Dogwood Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Primary Outcome
Change from Baseline in the weekly average of daily 24-hour pain intensity scores analyzed by percentage of responders among patients treated with Halneuron compared to Placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Halneuron
Study Locations (20)
Florida
- Central Recruiting Site - Jacksonville
- Central Recruiting Site - Jacksonville
- Central Recruiting Site - Lakeland
- Central Recruiting Site - Orlando
- Central Recruiting Site - Port Charlotte
- Central Recruiting Site - Tampa
California
- Central Recruiting Site - Fair Oaks
- Central Recruiting Site - Fountain Valley
- Central Recruiting Site - Los Angeles
- Central Recruiting Site - Santa Rosa
Missouri
- Central Recruiting Site - Fenton
- Central Recruiting Site - Kansas City
Alabama
- Central Recruiting Site - Sheffield
Arizona
- Central Recruiting Site - Glendale
Colorado
- Central Recruiting Site - Wheat Ridge
Georgia
- Central Recruiting Site - Atlanta
Illinois
- Central Recruiting Site - Gurnee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT06848348 shows while recruiting
NCT06848348 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Chemotherapy Induced Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06848348 names 20 study sites across 11 states, led by Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06848348 about?
NCT06848348 is a clinical study titled "Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain". A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
What is the current status of trial NCT06848348?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-02-21. Estimated completion is 2026-08.
What conditions does trial NCT06848348 study?
This clinical trial studies the following conditions: Chemotherapy Induced Neuropathic Pain.
What interventions are being tested in trial NCT06848348?
The interventions under investigation include: Placebo (DRUG), Halneuron (DRUG).
Who is sponsoring clinical trial NCT06848348?
This trial is sponsored by Dogwood Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06848348 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06848348's enrollment target sits among peer trials
200 304th of 2000 higher than 1,653 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI